Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective raised by JPMorgan Chase & Co. from $76.00 to $85.00 in a report released on Thursday. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price objective would suggest a potential upside of 9.02% from the company’s previous close.

AGIO has been the subject of a number of other reports. Credit Suisse Group boosted their price objective on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. Oppenheimer downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday. They noted that the move was a valuation call. Zacks Investment Research upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 price objective for the company in a research note on Tuesday, January 16th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 12th. Finally, ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Agios Pharmaceuticals has an average rating of “Buy” and a consensus price target of $81.00.

Shares of Agios Pharmaceuticals (AGIO) traded up $1.44 during trading hours on Thursday, hitting $77.97. The company had a trading volume of 1,079,500 shares, compared to its average volume of 823,580. The company has a market cap of $4,263.30, a P/E ratio of -12.44 and a beta of 2.12. Agios Pharmaceuticals has a 52 week low of $45.11 and a 52 week high of $82.96.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16). The company had revenue of $9.80 million for the quarter, compared to the consensus estimate of $12.65 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company’s revenue was down 56.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.34) earnings per share. sell-side analysts expect that Agios Pharmaceuticals will post -6.59 EPS for the current fiscal year.

In related news, insider Scott Biller sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $76.04, for a total value of $228,120.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David P. Schenkein sold 23,572 shares of the business’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $81.09, for a total value of $1,911,453.48. Following the completion of the transaction, the chief executive officer now directly owns 23,572 shares in the company, valued at $1,911,453.48. The disclosure for this sale can be found here. Over the last three months, insiders sold 183,114 shares of company stock worth $13,866,025. 5.43% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of AGIO. Alliancebernstein L.P. lifted its holdings in Agios Pharmaceuticals by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 21,742 shares of the biopharmaceutical company’s stock worth $1,119,000 after purchasing an additional 3,050 shares in the last quarter. Teachers Advisors LLC lifted its holdings in Agios Pharmaceuticals by 54.4% in the 2nd quarter. Teachers Advisors LLC now owns 46,733 shares of the biopharmaceutical company’s stock worth $2,404,000 after purchasing an additional 16,475 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in Agios Pharmaceuticals by 21.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 49,994 shares of the biopharmaceutical company’s stock worth $2,572,000 after purchasing an additional 8,965 shares in the last quarter. UBS Asset Management Americas Inc. lifted its holdings in Agios Pharmaceuticals by 3.2% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 27,088 shares of the biopharmaceutical company’s stock worth $1,394,000 after purchasing an additional 852 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Agios Pharmaceuticals by 31.3% in the 2nd quarter. Northern Trust Corp now owns 232,802 shares of the biopharmaceutical company’s stock worth $11,977,000 after purchasing an additional 55,560 shares in the last quarter. 82.74% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “JPMorgan Chase & Co. Increases Agios Pharmaceuticals (AGIO) Price Target to $85.00” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://theolympiareport.com/2018/02/15/jpmorgan-chase-co-increases-agios-pharmaceuticals-agio-price-target-to-85-00.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.